QualityStocks would like to highlight
Cannabics Pharmaceuticals, Inc. (
OTCQB: CNBX), founded in 2012 by a team of experts in the fields of molecular biology, cancer research, and pharmacology, who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.
In the company’s news,
Cannabics Pharmaceuticals has created a wide range of solutions for standardized, reproducible and easily administered medical cannabis therapies. The company’s flagship product, Cannabics SR, is a sustained release medical cannabis capsule that contains a pure extract of cannabinoids derived from select cannabis strains, embedded in a sophisticated lipid based formulation. The excipients of the proprietary sustained release formulation are all certified food-grade ingredients, free of artificial additives or chemical substances.
Cannabics SR capsules have been shown to provide beneficial therapeutic effects for 10-12 hours within the therapeutic window. To date, more than 100 patients in Israel – the majority of them oncology patients – have been treated with Cannabics SR capsules as a palliative therapy.
Cannabics Pharmaceuticals intends to launch a series of clinical studies of Cannabics SR capsules in leading medical centers in Israel where the company’s R&D division is strategically located. The results, combined with the superior pharmacokinetic profile of the Cannabics SR formulation, will be the key advantage of Cannabics Pharmaceuticals’ products over competing medical cannabis products available in the market.
Pivoting off of the trial data, the company plans to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. The company has recently achieved Good Manufacturing Practices (GMP) capabilities, thus ranking its products among a very limited number of medical cannabis products available in the US market that are manufactured according to these high-quality standards.
Cannabics Pharmaceuticals’ proprietary technologies are developed in certified laboratories and are licensed to certified manufacturers and distributors with adequate licenses in their local territories. Cannabics Pharmaceuticals itself does not manufacture, distribute, dispense or possess any controlled substances, including cannabis and cannabis-based preparations.
Co-founders Dr. Zohar Koren (CEO) and Dr. Eyal Ballan (CTO) guide the company’s operations with vast experience in medical research and pharmaceutical product development. Under their leadership, Cannabics Pharmaceuticals continues to develop its genetic and phenotipic database to provide superior treatments for incapacitating ailments for which there is no cure, building a pipeline of additional cannabis-based products for indications such as cancer, neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
